Minerva Neurosciences (NERV) Other financing activities (2014 - 2026)

Minerva Neurosciences (NERV) reported Other financing activities of $90875.0 for Q1 2026, down 17.97% quarter-over-quarter from $110782.0 in Q4 2025.

Minerva Neurosciences (NERV) Other financing activities (2014 - 2026) Analysis & Trends

Minerva Neurosciences has reported Other financing activities for 7 years, with the latest figure at $90875.0 in Q1 2026.

For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $90875.0; the trailing twelve-month figure through Mar 2026 stood at $288348.0 (changed N/A YoY), and the FY2023 full-year result was $396293.0, changed N/A from the prior year.
Other financing activities for Q1 2026 stood at $90875.0, down from $110782.0 in the prior quarter.
The five-year high for Other financing activities was $300000.0 in Q2 2023, with the low at $86691.0 in Q3 2023.
Historically, Other financing activities has averaged $147087.0 across 3 years, with a median of $100828.5 in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Minerva Neurosciences	197.55 Mn	197.55 Mn	-

Download Data